Tonix Pharmaceuticals Holding Corp. (TNXP) financial statements (2020 and earlier)

Company profile

Business Address 509 MADISON AVE. - SUITE 1608
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1125252635388
Cash and cash equivalents1125251919388
Short-term investments   715  
Other undisclosed current assets31111210
Total current assets:1426262746399
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000000
Intangible assets, net (including goodwill)00000 
Intangible assets, net (excluding goodwill)00000  
Restricted cash and investments0000000
Other undisclosed noncurrent assets  0000 
Total noncurrent assets:1000110
TOTAL ASSETS:1526272847409
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3322732
Accounts payable3111311
Accrued liabilities 111421
Debt0      
Due to related parties     00
Other undisclosed current liabilities2    (0)(0)
Total current liabilities:5322732
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0
Liabilities, other than long-term debt  00000
Deferred revenue and credits00000
Total noncurrent liabilities:0 00000
Total liabilities:5322732
Stockholders' equity
Stockholders' equity attributable to parent, including:924252540367
Common stock0000000
Additional paid in capital2272121871671439033
Accumulated other comprehensive income (loss)(0)(0)(0)(0)(0)0(0)
Accumulated deficit(217)(188)(162)(141)(102)(54) 
Other undisclosed stockholders' equity attributable to parent      (27)
Total stockholders' equity:924252540367
TOTAL LIABILITIES AND EQUITY:1526272847409

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:    0  
Operating expenses(29)(26)(21)(39)(48)(28)(11)
Other undisclosed operating loss    (0)  
Operating loss:(29)(26)(21)(39)(48)(28)(11)
Nonoperating income0000   
Investment income, nonoperating0000   
Gain on contract termination   0   
Other undisclosed income from continuing operations before equity method investments, income taxes  0000 
Net loss:(29)(26)(21)(39)(48)(28)(11)
Other undisclosed net income attributable to parent     00
Net loss attributable to parent:(29)(26)(21)(39)(48)(28)(11)
Preferred stock dividends and other adjustments(2)(3)     
Net loss available to common stockholders, diluted:(31)(29)(21)(39)(48)(28)(11)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(29)(26)(21)(39)(48)(28)(11)
Other comprehensive income000 00 
Comprehensive loss:(29)(26)(21)(39)(48)(28)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)(0)0(0)00
Comprehensive loss, net of tax, attributable to parent:(29)(26)(21)(39)(48)(28)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: